University Hospitals of Cleveland

Running trials

• Recruiting

  Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

  NCT07324031· AtaCor Medical, Inc.· Source

• Recruiting

  A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

  NCT07634471· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

  NCT07519772· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array

  NCT06936449· Cochlear· Source

• Recruiting

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  SpaceIT Hydrogel System for Perirectal Spacing

  NCT06451614· Boston Scientific Corporation· Source

• Recruiting

  Sacral Neuromodulation for Male Overactive Bladder (MOAB)

  NCT06511141· Axonics, Inc.· Source

• Active, not recruiting

  SIMPLAAFY Clinical Trial

  NCT06521463· Boston Scientific Corporation· Source

• Active, not recruiting

  Bionic Pancreas in CFRD

  NCT06449677· Phase 3· Jaeb Center for Health Research· Source

• Recruiting

  Study With [225Ac]Ac-FL-020 in mCRPC Participants

  NCT06492122· Phase 1· Full-Life Technologies UK Limited· Source

• Recruiting

  SW-682 in Advanced Solid Tumors

  NCT06251310· Phase 1· SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany· Source

• Recruiting

  PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

  NCT05934487· Endotronix, Inc.· Source

• Recruiting

  Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

  NCT05948943· Phase 2/3· Novartis Pharmaceuticals· Source

• Recruiting

  Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

  NCT06084481· Phase 1· AbbVie· Source

• Recruiting

  IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  NCT06119685· Phase 1/2· Indapta Therapeutics, INC.· Source

• Recruiting

  Nectero EAST System Clinical Study

  NCT06001918· Phase 2/3· Nectero Medical, Inc.· Source

• Recruiting

  A Study of ASP1002 in Adults for Treatment of Solid Tumors

  NCT05719558· Phase 1· Astellas Pharma Global Development, Inc.· Source

• Active, not recruiting

  A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

  NCT05662319· Phase 3· Sanofi· Source

• Active, not recruiting

  Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

  NCT05478304· AtriCure, Inc.· Source

• Active, not recruiting

  A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

  NCT05142696· Phase 1/2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

  NCT05250973· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  NCT05098132· Phase 1/2· Synthekine· Source

• Active, not recruiting

  Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

  NCT04790370· Phase 4· Boston Scientific Corporation· Source

• Active, not recruiting

  Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

  NCT04862286· Phase 3· AbbVie· Source

• Recruiting

  NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

  NCT04471909· Endospan Ltd.· Source

• Active, not recruiting

  CHAMPION-AF Clinical Trial

  NCT04394546· Boston Scientific Corporation· Source

• Active, not recruiting

  Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

  NCT04498117· Phase 3· CanariaBio Inc.· Source

• Active, not recruiting

  ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

  NCT03735667· Boston Scientific Corporation· Source

• Active, not recruiting

  Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

  NCT03539536· Phase 2· AbbVie· Source

• Recruiting

  Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

  NCT03536312· Ottawa Heart Institute Research Corporation· Source

• Recruiting

  Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

  NCT03435796· Phase 2/3· Celgene· Source

• Active, not recruiting

  Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

  NCT03108456· Abbott Medical Devices· Source

• Active, not recruiting

  Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

  NCT01744223· Phase 1/2· Bellicum Pharmaceuticals· Source

• Active, not recruiting

  Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

  NCT01617161· Massachusetts General Hospital· Source

• Recruiting

  Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

  NCT00288119· Case Western Reserve University· Source

• Active, not recruiting

  SDCC - Prospective Cohort Study of Chronic Renal Insufficiency

  NCT00304148· University of Pennsylvania· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Aortic aneurysm3 recruiting
• Prostate cancer3 recruiting
• Colorectal cancer2 recruiting
• Follicular lymphoma2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Lung cancer2 recruiting
• Barrett's oesophagus1 recruiting
• Childhood cancers1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Hearing loss1 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mesothelioma1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

  NCT07108153· Phase 2· Sionna Therapeutics Inc.· Source

• Completed

  Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

  NCT06865989· Insulet Corporation· Source

• Withdrawn

  Study of a Gene Therapy Treatment for Hemophilia A

  NCT06297486· Phase 3· Spark Therapeutics, Inc.· Source

• Terminated

  Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

  NCT05814666· Phase 2· Flamingo Therapeutics NV· Source

• Completed

  A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05601882· Phase 3· AbbVie· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Terminated

  STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

  NCT04807972· Phase 1· AbbVie· Source

• Terminated

  Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

  NCT04698915· Phase 2· Galera Therapeutics, Inc.· Source

• Terminated

  A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

  NCT04477291· Phase 1· Aptose Biosciences Inc.· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

  NCT04435600· Phase 3· AbbVie· Source

• Completed

  Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

  NCT03974113· Phase 2/3· Genzyme, a Sanofi Company· Source

• Completed

  SCOPE CLI (Shifting Care and Outcomes for Patients With Endangered Limbs - Critical Limb Ischemia)

  NCT03171259· Saint Luke's Health System· Source

• Completed

  Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

  NCT03955783· Phase 1· Sanjay Mohan· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Stemline Therapeutics, Inc.· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

  NCT03595059· Phase 1· AbbVie· Source

• Completed

  MIND: Artemis in the Removal of Intracerebral Hemorrhage

  NCT03342664· Penumbra Inc.· Source

• Completed

  Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

  NCT03271489· Phase 3· AbbVie· Source

• Completed

  A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

  NCT03213457· Phase 3· AbbVie· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Obstructive sleep apnoea14 works · 0 trials
• Ankylosing spondylitis10 works · 0 trials
• Long COVID and ME/CFS9 works · 0 trials
• Peripheral artery disease6 works · 1 trial
• Narcolepsy6 works · 0 trials
• Essential tremor3 works · 0 trials